Taysha Gene Therapies, Inc. (TSHA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Taysha Gene Therapies, Inc. (TSHA)
Company Performance

Current Price

as of Oct 18, 2024

$2.06

P/E Ratio

N/A

Market Cap

$422.18M

Description

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Metrics

Overview

  • HQDallas, TX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerTSHA
  • Price$2.06+1.48%

Trading Information

  • Market Cap$422.18M
  • Float77.33%
  • Average Daily Volume (1m)1,705,963
  • Average Daily Volume (3m)1,451,128
  • EPS-$0.87

Company

  • Revenue$12.87M
  • Rev Growth (1yr)-53.57%
  • Net Income-$20.93M
  • Gross Margin73.02%
  • EBITDA Margin-1,888.40%
  • EBITDA-$21.00M
  • EV$406.05M
  • EV/Revenue31.54
  • P/EN/A
  • P/S37.26
  • P/B3.81
Documents
SEC Filings
8-K (2024-08-12)
8-K (2024-06-26)
8-K (2024-06-18)
8-K (2024-05-30)
8-K (2024-05-14)
8-K (2024-03-19)
8-K (2024-01-10)
8-K (2023-12-20)
8-K (2023-11-15)
8-K (2023-11-14)
8-K (2023-11-01)
8-K (2023-09-26)
8-K (2023-09-19)
8-K (2023-08-29)
8-K (2023-08-24)
8-K (2023-08-14)
8-K (2023-08-04)
8-K (2023-07-31)
8-K (2023-06-28)
8-K (2023-06-23)
8-K (2023-06-22)
8-K (2023-06-06)
8-K (2023-06-05)
8-K (2023-05-19)
8-K (2023-05-15)
8-K (2023-04-27)
8-K (2023-03-28)
8-K (2023-01-31)
8-K (2023-01-19)
10-Q (2024-08-12)
10-Q (2024-05-14)
10-Q (2023-11-14)
10-Q (2023-08-14)
10-Q (2023-05-11)
10-K (2024-03-19)
10-K (2023-03-28)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-14)
Earnings Report (2023-05-11)
Factset
Factset Business Description
Factset Street Account
Taysha Gene Therapies reports Q3 EPS ($0.93) vs FactSet ($0.17) [10 est, ($0.31)-(0.09)] ($1.32, 0.00) (2023-11-14T21:09:25Z)
Taysha Gene Therapies receives $40M term loan commitment from Trinity Capital ($1.54, 0.00) (2023-12-19T12:35:13Z)
Taysha Gene Therapies presents new preclinical in-vitro data on TSHA-102 in Rett syndrome supporting miRARE regulation of MECP2 expression at ESGCT 2023 ($2.18, 0.00) (2023-10-24T12:06:40Z)
Taysha Gene Therapies announces expanded eligibility in REVEAL Phase 1/2 adult trial to include adolescent Rett syndrome patients ($1.79, 0.00) (2023-11-29T13:01:20Z)